REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Result of general meeting

9 Feb 2015 10:17

RNS Number : 3518E
4d Pharma PLC
09 February 2015
 

4D pharma plc

(the 'Company' or '4D')

Result of general meeting

 

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.

 

As a result, the placing announced on 21 January 2015 of 8,475,610 new ordinary shares at 410p per ordinary share to raise £34.75m, is conditional only on Admission which is expected to take place on 10 February 2015.

 

Following Admission, the Company's issued share capital will consist of 60,567,729 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that following Admission, the total number of voting rights in the Company will be 60,567,729.

 

For further information please contact:

4D

+ 44 (0) 161 837 6205

Duncan Peyton, Chief Executive Officer

 

Zeus Capital Limited - Nomad and Broker

Ross Andrews/Dan Bate

+44 (0) 161 831 1512

Dominic Wilson

+44 (0) 20 7533 7727

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUQCPUPAGGR

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.